Aura Biosciences, Inc. (NASDAQ:AURA) Receives Consensus Rating of “Buy” from Analysts

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given a consensus recommendation of “Buy” by the eight brokerages that are presently covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $22.75.

A number of research firms have recently weighed in on AURA. JMP Securities set a $19.00 target price on Aura Biosciences in a research report on Wednesday, March 26th. HC Wainwright set a $25.00 target price on Aura Biosciences in a research note on Tuesday, March 25th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a report on Friday, January 31st. Finally, Citigroup reissued an “outperform” rating on shares of Aura Biosciences in a report on Wednesday, March 26th.

Insiders Place Their Bets

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the sale, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. The trade was a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 23,045 shares of company stock valued at $177,242 in the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets bought a new stake in Aura Biosciences during the fourth quarter valued at $50,000. GAMMA Investing LLC lifted its position in shares of Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company’s stock valued at $57,000 after acquiring an additional 9,573 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Aura Biosciences during the fourth quarter worth $87,000. ProShare Advisors LLC bought a new position in Aura Biosciences during the fourth quarter worth $127,000. Finally, Harvest Investment Services LLC acquired a new stake in Aura Biosciences in the fourth quarter worth $133,000. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Trading Down 7.3 %

Aura Biosciences stock opened at $4.97 on Friday. The company has a market capitalization of $249.62 million, a price-to-earnings ratio of -2.87 and a beta of 0.43. The stock’s 50 day moving average is $7.01 and its 200-day moving average is $8.30. Aura Biosciences has a 12 month low of $4.84 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.09). As a group, equities research analysts predict that Aura Biosciences will post -1.66 earnings per share for the current fiscal year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.